Compound ID | 1250
Class: Tetracycline
Spectrum of activity: | Gram-positive & Gram-negative |
Details of activity: | For the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by Streptococcus pneumoniaeand for the treatment of asymptomatic carriers of Neisseria meningitidis. |
Description: | Semisynthetic sancycline derivative |
Highest developmental phase: | Approved by FDA in 1992 |
Development status: | Approved |
Reason Dropped: | Several drug formulations discontinued |
Chemical structure(s): | |||||||||||
|
|
External links: | |
PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/54675783 |
Guide to Pharmacology: | minocycline |
Citations: |
|